National Study Finds Didanosine Better Than Zidovudine For HIV-Infected Kids

June 12, 1997

CHAPEL HILL -- Children infected with the virus that causes AIDS fare better on a drug known as didanosine, or ddI, than on the more widely known drug zidovudine, according to a multicenter study conducted across the United States and in Puerto Rico.

The study, published in Thursday's (June 12) issue of the New England Journal of Medicine, showed that a combination of didanosine and zidovudine, formerly called AZT, was superior to zidovudine alone in slowing progression of the illness and delaying death. It also revealed that didanosine alone worked even better than the combination because of fewer side effects.

"These somewhat surprising findings are new and important because until now, zidovudine has been the drug of choice for treating children who have AIDS-related symptoms," said Dr. Wilma Lim, clinical assistant professor of pediatrics at the University of North Carolina at Chapel Hill School of Medicine and a contributor to the study. "This large, long-term carefully done study shows zidovudine is not as good."

Lim treats children infected with HIV -- the AIDS virus -- every day.

Dr. Janet A. Englund of Baylor College of Medicine coordinated the study, which involved scores of researchers at 78 hospitals from North Carolina to California. In what is known as a randomized, double-blind clinical trial, researchers evaluated how 831 children did on either drug or on a combination of the two.

HIV-infected children, 90 percent of whom were infected at birth, were enrolled between August 1991 and August 1993. They were divided into two age groups -- below and above 30 months old -- and randomly assigned to one of the three treatment groups. Ninety-two percent had not received such antiretroviral therapy before. Such drugs are called nucleoside analogues.

"An analysis of how the children were doing after an average of 23 months showed a significantly higher risk of disease progression or death among patients receiving zidovudine alone than in those receiving the other two treatments," Lim said. "For that reason, that part of the study was stopped, and the research continued with the combination treatment or didanosine alone."

After nearly three years, analysis of results nationwide showed that children who received didanosine alone faced a lower risk of anemia or blood cell damage, she said. The study also showed children tolerate long-term antiretroviral therapy.

"Despite growing optimism that combination antiviral regimens, particularly those that include a protease inhibitor, can delay disease progression and prolong survival in HIV-infected adults, serious hurdles must be overcome before such therapy can be routinely applied to pediatric patients," Englund wrote.

"Important problems remain, such as the lack of data to ensure safe and effective dosing and the unavailability of these drugs in palatable suspensions," she said. "Although protease inhibitors appear promising, data substantiating the superiority of combinations containing protease inhibitors to nucleoside analogues in children are not yet available."

Numerous studies are under way that compare newer, possibly better combinations of drugs for children, Lim said.

In North Carolina, research nurse Virginia Dudek of UNC-CH also collaborated in the study, as did Drs. Ross E. McKinney and Karen O'Donnell, nurse Barbara Lane and physician?s associate Megan Valentine at Duke University.

Slightly more than 54 percent of the children were black, 30 percent were Hispanic, almost 14 percent were white, and the rest came from other racial or ethnic groups.

Glaxo-Wellcome Pharmaceuticals produces zidovudine, and Bristol-Myers Squibb Pharmaceuticals produces didanosine.

Note: Lim's number is (919) 966-2331. She can be paged by calling 966-4140 and entering 4906.

University of North Carolina at Chapel Hill

Related Aids Articles from Brightsurf:

Developing a new vaccination strategy against AIDS
Infection researchers from the German Primate Center (DPZ) -- Leibniz Institute for Primate Research have in cooperation with international colleagues tested a new vaccination strategy against the HIV-related simian immunodeficiency virus (SIV) in rhesus monkeys.

HIV-AIDS: Following your gut
Researchers find a way to reduce replication of the AIDS virus in the gastrointestinal tract.

A path toward ending AIDS in the US by 2025
Using prevention surveillance data to model rates of HIV incidence, prevalence and mortality, investigators at Brigham and Women's Hospital and Johns Hopkins Bloomberg School of Public Health set targets, specifically a decrease in new infections to 21,000 by 2020 and to 12,000 by 2025, that would mark a transition toward ending the HIV/AIDS epidemic.

What does it take for an AIDS virus to infect a person?
Researchers examined the characteristics of HIV-1 strains that were successful in traversing the genital mucosa that forms a boundary to entry by viruses and bacteria.

How AIDS conquered North America
A new technique that allowed researchers to analyze genetic material from serum samples of HIV patients taken before AIDS was known provides a glimpse of unprecedented detail into the beginnings of the AIDS epidemic in North America.

New research could help build better hearing aids
Scientists at Binghamton University, State University of New York want to improve sensor technology critical to billions of devices made every year.

NY State Department of Health AIDS Institute funds HIV/AIDS prevention in high-risk youth
NewYork-Presbyterian's Comprehensive Health Program and Project STAY, an initiative of the Harlem Heath Promotion Center (HHPC) at Columbia University's Mailman School of Public Health has received two grants totaling more than $3.75 million from the New York State Department of Health AIDS Institute for their continued efforts to prevent HIV/AIDS in at-risk youth.

A new way to nip AIDS in the bud
When new HIV particles bud from an infected cell, the enzyme protease activates to help the viruses infect more cells.

AIDS research prize for Warwick academic
A researcher at the University of Warwick has received international recognition for his contribution to AIDS research.

Insects inspire next generation of hearing aids
An insect-inspired microphone that can tackle the problem of locating sounds and eliminate background noise is set to revolutionize modern-day hearing aid systems.

Read More: Aids News and Aids Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to